Director, Allogeneic Hematopoietic Stem Cell Transplantation, Princess Margaret Cancer Centre

Ref: 3150

University Health Network

Toronto, Ontario, Canada

Apply Now

Role Managed by:

Ainsley Brown

Consultant

t: +1 604-558-5127

e: ainsley.brown@perrettlaver.com

Primary Practice Group: Academic Medicine and Health Sciences

Salary & Benefits: Competitive

Closing Date: 15/09/2017

This vacancy has now expired, and is not accepting any new applications.

Please search for live opportunities or use the Register Interest facility to sign up for job alerts and/or leave your CV speculatively.

University Health Network

Director, Allogeneic Hematopoietic Stem Cell Transplantation, Princess Margaret Cancer Centre, University Health Network

The Princess Margaret Cancer Centre is part of the University Health Network (UHN) and works together with Toronto General Hospital, Toronto Western Hospital, Princess Margaret Cancer Centre, and the Toronto Rehabilitation Institute as part of the larger research mission at UHN. We are the largest comprehensive cancer centre in Canada and considered one of the top 5 in the world. The Division of Medical Oncology and Hematology is the largest comprehensive program of its kind in Canada and dedicated to providing some of the most advanced and novel approaches to medical and hematologic oncology worldwide.

The Princess Margaret is currently expanding its Allogeneic Hematopoietic Stem Cell Transplantation (AlloHCT) Program and is seeking a Director to provide leadership during an exciting period of growth and transformation. Our Program is the largest of its kind in Canada, currently performing ~130 related and unrelated donor allogeneic transplants per year, and targeted to more than double in size over the next three years. The Program is supported by two inpatient units, dedicated outpatient facilities, and a state-of-the-art GMP cell processing facility, which also supports the Autologous Transplant Program, as well as a widely-recognized transplantation program. Many opportunities for collaboration exist such as a close relationship between the transplant program and the leukemia site group, the latter being the largest program in Canada, and among the largest in North America.

As an international leader in the area of AlloHCT, the successful candidate will be appointed at the Associate or Full Professor level in the Department of Medicine at the University of Toronto, and will be a candidate for the Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation at the University Health Network. This Chair benefits from a $2 million endowment obtained through the generous support of Seymour Epstein’s $1 million gift and the work of The Princess Margaret Cancer Foundation.

The Director of AlloHCT sits within the Division of Medical Oncology and Hematology and reports directly to the Division Head. The Director is expected to coordinate the clinical and research activities of the AlloHCT group, as well as being involved in patient care, teaching, and research. The successful candidate should be eligible for registration with the College of Physicians and Surgeons of Canada (or equivalent).

UHN is partnering with the executive search firm Perrett Laver on this search process. Further information, including details of how to apply, can be downloaded at http://www.perrettlaver.com/candidates quoting reference 3150. For informal inquiries, please contact Audrey Gamet at Audrey.Gamet@perrettlaver.com or +1 312 380 0797.

The deadline for applications is noon EST on Friday 15 September, 2017

This vacancy has now expired, and is not accepting any new applications.

Please search for live opportunities or use the Register Interest facility to sign up for job alerts and/or leave your CV speculatively.